Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8581 to 8595 of 8900 results

  1. NICE to stop supplying print copies of BNF and BNFC

    To support use of up-to-date content, and drive sustainability and digital transformation, the upcoming editions of BNF and BNFC (scheduled for distribution in October and November 2023) will be the last print editions to be supplied to the NHS in England by NICE.

  2. Up to 6,000 people set to benefit after NICE recommends new life-extending drug for advanced prostate cancer

    People living with metastatic prostate cancer in England will gain access to a new treatment combination from today (Friday, 24 October), following a recommendation by NICE.

  3. Shaping the future of global health technology assessment

    Learn about our role in the new international Health Economics Methods Advisory (HEMA) and its ambitions to make a real difference to patients around the world.

  4. Record numbers accessing HIV prevention treatment

    Pre-exposure prophylaxis (PrEP) became routinely available through sexual health clinics in 2020, with NICE recommending the tablets for people at high risk of HIV in 2021.

  5. First HIV prevention injection for people unable to have daily PrEP recommended

    A ground-breaking HIV-1 prevention injection has been recommended by NICE, marking a significant advance for a small group of adults and young people unable to have daily pre-exposure prophylaxis (PrEP) tablets.

  6. Our chief executive, Dr Sam Roberts, welcomes the government's 10 Year Plan for healthcare

    The government's 10 Year Plan marks a pivotal moment for healthcare and strengthens NICE’s role.

  7. How NICE is helping to deliver the government's 10 Year Plan for healthcare

    Home News Podcasts How NICE is helping to deliver the government's 10 Year Plan for healthcare Podcasts 30 September 2025 Listen About this

  8. Tackling variation in rehab for people with neurological conditions

    NICE has recommended a standardised approach for rehabilitation, to address the variation of care experienced by millions of people with chronic neurological conditions.

  9. Should NICE's cost-effectiveness thresholds change?

    We explore the ongoing debate around NICE’s cost-effectiveness thresholds and what the future holds.

  10. Same time decisions on licensing and value - what pharmaceutical companies need to know

    Learn how NICE and MHRA are launching an aligned pathway to accelerate patient access to medicines and provide a more efficient route for industry.

  11. NICE joins international collaboration on HTA methods research

    We’ve partnered with the USA-based Institute for Clinical and Economic Review (ICER) and the Canadian Drug Agency (CDA-AMC) to establish the Health Economics Methods Advisory (HEMA), a new international initiative to research and evaluate health technology assessment (HTA) methods.

  12. From bedside to boardroom - an Executive MSc journey

    NICE has been working in partnership with the London School of Economics and Political Science (LSE) to jointly develop and deliver an Executive MSc in Healthcare Decision-Making. Discover how this advanced healthcare training bridges clinical practice and system-wide decision-making through one committee member's transformative journey.

  13. NICE expands HealthTech evaluations for NHS patients

    The new approach puts HealthTech on equal footing with medicines, ensuring innovations like wearable diabetes monitors and AI diagnostics reach patients faster and more consistently across the NHS.

  14. Our first guideline on kidney cancer recommends better use of biopsies to avoid surgery

    New guidance aims to reduce variation in treatment and prevent unnecessary surgery, improving care for patients and supporting healthcare professionals.

  15. Hundreds of people set to benefit after life-extending lung cancer treatment given green light

    Targeted immunotherapy found to significantly increase overall survival rates for people with an aggressive form of lung cancer has been recommended by NICE.